BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 23545045)

  • 1. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.
    Miller MJ; Foy KC; Kaumaya PT
    Discov Med; 2013 Mar; 15(82):166-76. PubMed ID: 23545045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New era of tumor immunotherapy].
    Yoshitake Y; Nakatsura T; Nishimura Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
    [No Abstract]   [Full Text] [Related]  

  • 5. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
    Gjerstorff MF; Burns J; Ditzel HJ
    Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Peptide-based vaccine therapy for cancer patients].
    Yamada A
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():602-7. PubMed ID: 15861717
    [No Abstract]   [Full Text] [Related]  

  • 9. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.
    Kaumaya PT; Foy KC
    Future Oncol; 2012 Aug; 8(8):961-87. PubMed ID: 22894670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EGF receptor family as targets for cancer therapy.
    Mendelsohn J; Baselga J
    Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.
    Kaumaya PT
    Hum Vaccin Immunother; 2015; 11(6):1368-86. PubMed ID: 25874884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epitope peptide vaccine with oncoantigen for cancer and its biomarker].
    Hazama S; Maeda K; Oka M
    Nihon Rinsho; 2012 Dec; 70(12):2189-93. PubMed ID: 23259395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New directions in immunotherapy for malignant solid tumors].
    Okuno K; Sugiura F; Sukegawa Y; Inoue K
    Nihon Rinsho; 2012 Dec; 70(12):2075-86. PubMed ID: 23259377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
    Moschella F; Proietti E; Capone I; Belardelli F
    Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.
    Shapira S; Lisiansky V; Arber N; Kraus S
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S67-77. PubMed ID: 20374033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J; Mackiewicz A
    Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.